Search

Pomalidomide prolongs survival in refractory myeloma patients

MM-003 is a large, multi-centre phase 3 study that assessed the efficacy and safety of a new drug, Pomalidomide (POM) in combination with low-dose dexamethasone (POM+LoDex) and compared this combination with high dose dexamethasone in MM patients with late stage…

Read more

Statement of Solidarity after Earthquake in Morocco

On behalf of the European Hematology Association, I would like to express my deepest condolences and heartfelt support to the people of Morocco who have been affected by the recent earthquake.

Read more

EHA-ASH Translational Research Training in Hematology

TRTH 2025 call is now closed. What is Translational Research Training in Hematology?Translational Research Training in Hematology (TRTH) provides early-career researchers with a unique, year-long training and mentoring experience.

Read more

Introducing YoungEHA: you don’t have to grow old to make a difference

By Dr. Fabienne Lucas, MD PhD, YoungEHA Committee. Hearing exciting new research, attending lectures by leaders in the field, and networking are some of the obvious things that are happening during the annual EHA congress.

Read more

Training vital for new era of patient-centric healthcare

Christine Chomienne, president of the European Hematology Association (EHA), was speaking at the third annual conference of the European Alliance for Personalised Medicine (EAPM) – a Brussels-based organization that brings together stakeholders from academia, through research,…

Read more

EHA-SWG Scientific Meeting on MDS/MPN/AML: Commonalities and Differences of Myeloid Neoplasms

Join us for this unique and rare opportunity and exchange ideas with MDS, MPN, and AML experts in one meeting. Internationally renowned experts will provide presentations and share the recent developments and answers to your clinical questions.

Read more